Paxman AB (publ) (PXMBF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Paxman AB (publ) (PXMBF) trades at $2.80 with AI Score 56/100 (Grade B). Paxman AB (publ) develops and sells scalp cooling systems designed to minimize hair loss during chemotherapy. Market cap: $119.90M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for PXMBF: PXMBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PXMBF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
PXMBF: 1/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Paxman AB (publ) (PXMBF) Healthcare & Pipeline Overview
Paxman AB (publ) specializes in scalp cooling technology to reduce chemotherapy-induced hair loss, holding a unique position in the medical devices market. With a global presence and a focus on cancer care, the company caters to hospitals and cancer centers, offering a solution to improve patients' quality of life during treatment.
What Is the Investment Thesis for PXMBF?
Paxman AB (publ) presents a focused investment opportunity within the medical devices sector, specifically targeting the reduction of chemotherapy-induced hair loss. With a market capitalization of $119.90M, the company operates with a gross margin of 47.7%. Growth catalysts include expansion into new geographic markets and further development of its cooling technology. The collaboration with National University Hospital in Singapore for portable cooling devices represents a potential avenue for product diversification. However, the company's negative P/E ratio of -64.98 and a profit margin of -5.1% indicate profitability challenges. Investors should closely monitor the company's ability to improve its financial performance and capitalize on its market position. Key value drivers include increased adoption of scalp cooling systems in cancer treatment protocols and successful commercialization of new product innovations.
Based on FMP financials and quantitative analysis
PXMBF Key Highlights
- Market capitalization of $119.90M indicates Paxman AB's current valuation in the medical device market.
- Gross margin of 47.7% reflects the profitability of Paxman AB's scalp cooling system sales.
- Beta of 0.45 suggests lower volatility compared to the overall market.
- Negative P/E ratio of -64.98 indicates current losses, requiring investor attention to future profitability.
- Profit margin of -5.1% highlights the need for improved cost management and revenue growth.
Who Are PXMBF's Competitors?
PXMBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BCCOY BICO Group AB (publ) | $0.50 | +0.00% | $141.15M | 46 |
| CLLKF BICO Group AB (publ) | $1.76 | +0.00% | $121.71M | 47 |
| HOFBF Hofseth BioCare ASA | $0.17 | +0.00% | $65.82M | 43 |
| IMPZY Implanet S.A. | $0.08 | +0.00% | $230.11M | 53 |
| LDXHF Lumos Diagnostics Holdings Limited | $0.08 | +0.00% | $61.07M | 40 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PXMBF's Key Strengths?
- Specialized product offering addressing a specific need in cancer care.
- Global distribution network and established customer base.
- Research collaborations with leading medical institutions.
- Strong brand reputation in the scalp cooling market.
What Are PXMBF's Weaknesses?
- Negative profitability metrics (P/E and profit margin).
- Reliance on a single product category.
- Limited financial resources compared to larger medical device companies.
- Exposure to regulatory changes in different countries.
What Could Drive PXMBF Stock Higher?
- Publication of clinical trial results demonstrating the efficacy of Paxman Scalp Cooling System (timeline: Q4 2026).
- Expansion of distribution network into new geographic regions (timeline: ongoing).
- Strategic partnerships with leading cancer centers and hospitals (timeline: ongoing).
- Regulatory approvals for portable cooling devices in key markets (timeline: 2027).
What Are the Key Risks for PXMBF?
- Negative return on equity (-2.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Competition from alternative methods for managing chemotherapy side effects.
- Regulatory hurdles and reimbursement challenges in certain markets.
- Negative profitability metrics (P/E and profit margin).
- Economic downturns affecting healthcare spending.
- Technological advancements rendering current products obsolete.
What Are the Growth Opportunities for PXMBF?
- Expansion into Emerging Markets: Paxman AB has the opportunity to expand its presence in emerging markets across Asia and South America, where access to advanced cancer care is growing. These regions represent a significant untapped market for scalp cooling systems, driven by increasing cancer incidence rates and a rising awareness of supportive care options. Successful penetration into these markets could substantially increase Paxman AB's revenue and market share. Timeline: 2-3 years.
- Product Diversification with Portable Cooling Devices: The research collaboration with National University Hospital in Singapore to develop portable cooling and compression devices presents a significant growth opportunity. These devices could address a broader range of medical applications beyond chemotherapy-induced hair loss, potentially including pain management and post-operative recovery. Successful development and commercialization of these devices could diversify Paxman AB's product portfolio and revenue streams. Timeline: 3-5 years.
- Strategic Partnerships with Cancer Centers: Forming strategic partnerships with leading cancer centers and hospitals worldwide can enhance Paxman AB's market reach and credibility. These partnerships can facilitate the integration of Paxman's scalp cooling systems into standard chemotherapy treatment protocols, increasing adoption rates and driving revenue growth. Furthermore, collaborative research initiatives with these institutions can lead to the development of innovative solutions and improved patient outcomes. Timeline: Ongoing.
- Increased Awareness and Education: Investing in awareness campaigns and educational programs for healthcare professionals and patients can drive greater adoption of scalp cooling technology. By highlighting the benefits of Paxman's systems in reducing chemotherapy-induced hair loss and improving patients' quality of life, the company can overcome barriers to adoption and increase demand. This includes participating in medical conferences, publishing clinical studies, and providing training resources for healthcare providers. Timeline: Ongoing.
- Technological Advancements in Cooling Efficiency: Continuous innovation in scalp cooling technology to improve cooling efficiency and patient comfort represents a key growth opportunity. Developing systems that offer faster cooling times, more precise temperature control, and enhanced user-friendliness can differentiate Paxman AB's products from competitors and attract a wider range of customers. This includes exploring advanced materials, improved cooling algorithms, and ergonomic design features. Timeline: 1-2 years.
What Opportunities Does PXMBF Have?
- Expansion into emerging markets with growing cancer incidence rates.
- Product diversification with portable cooling and compression devices.
- Strategic partnerships with cancer centers and hospitals.
- Increased awareness and education about scalp cooling technology.
What Threats Does PXMBF Face?
- Competition from alternative methods for managing chemotherapy side effects.
- Regulatory hurdles and reimbursement challenges in certain markets.
- Economic downturns affecting healthcare spending.
- Technological advancements rendering current products obsolete.
What Are PXMBF's Competitive Advantages?
- Specialized expertise in scalp cooling technology.
- Established brand reputation in the chemotherapy support market.
- Global distribution network and customer base.
- Research collaborations with leading medical institutions.
- Intellectual property protection for cooling system designs.
What Does PXMBF Do?
Paxman AB (publ) was founded in 1996 with the mission of minimizing hair loss associated with chemotherapy treatments. The company's core product, the Paxman Scalp Cooling System, is designed to alleviate the distressing side effect of chemotherapy-induced alopecia. This system is distributed across Europe, the United States, Mexico, Japan, Oceania, and South and Central America, reaching a global network of cancer centers and hospitals. Paxman AB collaborates with medical institutions, such as the National University Hospital in Singapore, to develop innovative solutions like portable cooling and compression devices. The company's focus remains on enhancing the patient experience during cancer treatment by addressing a significant concern related to chemotherapy. Based in Karlshamn, Sweden, Paxman AB continues to expand its reach and refine its technology to improve the lives of cancer patients worldwide.
What Products and Services Does PXMBF Offer?
- Develops scalp cooling systems to minimize hair loss during chemotherapy.
- Sells Paxman Scalp Cooling Systems to cancer centers and hospitals.
- Provides solutions for patients undergoing chemotherapy treatment.
- Offers a technology to alleviate chemotherapy-induced alopecia.
- Collaborates with medical institutions for research and development.
- Distributes products across Europe, the United States, and other regions globally.
How Does PXMBF Make Money?
- Direct sales of Paxman Scalp Cooling Systems to hospitals and cancer centers.
- Service and maintenance contracts for installed systems.
- Partnerships with distributors in various geographic regions.
- Research and development collaborations for new product innovations.
What Industry Does PXMBF Operate In?
Paxman AB (publ) operates within the medical devices industry, specifically focusing on supportive care for cancer patients. The market for devices that mitigate chemotherapy side effects is growing, driven by increased awareness and patient demand for improved quality of life during treatment. Competitors include companies like BCCOY (Belmont Capital Corp), CLLKF (Cantel Medical Corp), and HOFBF (Hologic Inc), which offer various medical devices and solutions for cancer care. Paxman AB distinguishes itself through its specialization in scalp cooling technology, addressing a specific and often distressing side effect of chemotherapy.
Who Are PXMBF's Key Customers?
- Cancer centers and oncology clinics.
- Hospitals with chemotherapy treatment facilities.
- Patients undergoing chemotherapy treatment for various cancers.
- Distributors of medical devices in different countries.
How Paxman AB (publ) Is Valued
Paxman AB (publ) carries a market capitalization of $119.90M, placing it in the micro-cap category. Relative to its peer group, PXMBF's quantitative score of 56/100 is above the peer average of 46/100.
Company Profile
Paxman AB (publ) operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Karlshamn, SE. The company is led by CEO Richard Paxman. PXMBF has traded publicly since 2019.
ROE -3%Key Financial Metrics
Return on equity for Paxman AB (publ) stands at -2.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.54 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Paxman AB (publ)'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 14.22 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Paxman AB (publ) revenue of about $409.2M for fiscal 2026, with EPS near $1.84.
PXMBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Insider buying has increased recently, indicating confidence from management in the company's future prospects.
- Community sentiment has been leaning positive, with discussions highlighting the company's innovative product pipeline.
- Recent partnerships have been formed, suggesting a growing market presence and potential for revenue expansion.
- The focus on sustainability aligns with broader market trends, attracting investors who prioritize environmental responsibility.
Bear Case
- Concerns about regulatory challenges in the healthcare sector have surfaced, creating uncertainty around operational capabilities.
- Social media sentiment has seen some bearish commentary, particularly regarding competition in the market.
- Recent earnings reports have not met market expectations, leading to skepticism about growth projections.
- Market perception has been cautious, with some analysts questioning the scalability of Paxman's business model in a competitive landscape.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PXMBF Latest News
No recent news available for PXMBF.
PXMBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PXMBF.
Price Targets
Wall Street price target analysis for PXMBF.
PXMBF MoonshotScore
What does this score mean?
The MoonshotScore rates PXMBF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Richard Paxman
CEO
Richard Paxman serves as the CEO of Paxman AB (publ), bringing extensive experience in the medical device industry. His career spans various leadership roles focused on commercial strategy, product development, and market expansion. Paxman's background includes a strong emphasis on innovation and patient-centric solutions. He holds a degree in Business Administration and has completed executive education programs in healthcare management. His expertise is pivotal in guiding Paxman AB's strategic direction and growth initiatives.
Track Record: Under Richard Paxman's leadership, Paxman AB has expanded its global presence and strengthened its position in the scalp cooling market. Key achievements include securing regulatory approvals in new territories, forging strategic partnerships with leading cancer centers, and driving the development of innovative cooling technologies. Paxman has overseen the company's efforts to increase awareness and adoption of scalp cooling as a standard of care for chemotherapy patients. He manages 105 employees.
PXMBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Paxman AB (publ) may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries a higher degree of risk due to the potential for limited information, price volatility, and liquidity constraints.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for price manipulation and volatility.
- Lower trading volume and liquidity constraints.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight compared to major exchanges.
- Verify the company's financial statements and disclosures.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal standing.
- Monitor trading volume and price volatility.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established business operations and product offerings.
- Research collaborations with reputable medical institutions.
- Global distribution network and customer base.
- Positive media coverage and industry recognition.
- Presence of experienced management team.
Paxman AB (publ) Healthcare Stock: Key Questions Answered
What does Paxman AB (publ) do?
Paxman AB (publ) specializes in the development, manufacturing, and distribution of the Paxman Scalp Cooling System, a medical device designed to minimize hair loss in patients undergoing chemotherapy treatment. The company's system is used in cancer centers and hospitals worldwide, providing a solution to alleviate the distressing side effect of chemotherapy-induced alopecia. Paxman AB focuses on improving the quality of life for cancer patients by addressing a significant concern related to their treatment.
What do analysts say about PXMBF stock?
Analyst coverage for PXMBF is limited due to its OTC listing and smaller market capitalization. Key valuation metrics include a negative P/E ratio, reflecting current losses, and a gross margin of 47.7%, indicating the profitability of its core product. Growth considerations include expansion into new markets, product diversification, and increased adoption of scalp cooling technology. Investors should conduct thorough due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for PXMBF?
The main risks for Paxman AB (publ) include competition from alternative methods for managing chemotherapy side effects, regulatory hurdles and reimbursement challenges in certain markets, and the company's current negative profitability metrics. Additionally, economic downturns could affect healthcare spending, and technological advancements could render current products obsolete. Investing in PXMBF also carries the risks associated with OTC stocks, such as limited liquidity and transparency.
How does Paxman AB (publ) navigate regulatory approval processes?
Paxman AB (publ) navigates regulatory approval processes by adhering to stringent quality standards and complying with the requirements of regulatory bodies such as the FDA in the United States and the EMA in Europe. The company maintains detailed documentation of its product development, manufacturing, and clinical testing processes to support its regulatory submissions. Paxman AB also collaborates with regulatory consultants and experts to ensure compliance with evolving regulations and to expedite the approval process for its products in different markets.
What is Paxman AB (publ)'s strategy for maintaining its competitive advantage in the scalp cooling market?
Paxman AB (publ) maintains its competitive advantage in the scalp cooling market through continuous innovation, strategic partnerships, and a focus on customer satisfaction. The company invests in research and development to improve the efficiency and user-friendliness of its scalp cooling systems. Paxman AB also collaborates with leading cancer centers and hospitals to integrate its systems into standard chemotherapy treatment protocols. Furthermore, the company provides comprehensive training and support to healthcare professionals to ensure optimal utilization of its products and to enhance patient outcomes.
What are the key factors to evaluate for PXMBF?
Paxman AB (publ) (PXMBF) holds an AI score of 56/100 (moderate). Not financial advice.
How frequently does PXMBF data refresh on this page?
PXMBF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PXMBF's recent stock price performance?
Paxman AB (publ) (PXMBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product offering addressing a specific need in cancer care. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for PXMBF due to its OTC listing.
- Financial data based on available information and may be subject to change.
- OTC market investments carry higher risks than exchange-listed stocks.